<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778644</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2020-0367</org_study_id>
    <nct_id>NCT04778644</nct_id>
  </id_info>
  <brief_title>Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task</brief_title>
  <official_title>Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been&#xD;
      extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has&#xD;
      antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential&#xD;
      antipsychotic treatment. The purpose of this pilot research is to show target engagement of&#xD;
      the hippocampus with the study drug (CBD versus placebo) in patients who have been diagnosed&#xD;
      with schizophrenia, schizoaffective disorder, or bipolar disorder with psychosis compared to&#xD;
      healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conjecture that CBD may act both to modify THC effects and to reduce&#xD;
      psychosis symptoms (at least in part) through downstream ECS-related mechanisms, both of&#xD;
      which actions converge on the hippocampus, a region rich in CB1 receptors. As such, observing&#xD;
      hippocampus activity levels using fMRI can be an effective means of measuring CBD target&#xD;
      engagement within this pilot study context. The purpose of this pilot research is to show&#xD;
      target engagement of the hippocampus with the study drug cannabidiol (CBD) versus placebo, in&#xD;
      BSNIP Biotype 3 compared to Biotypes 1 and 2 and to healthy control subjects, during&#xD;
      performance of an fMRI paired associated memory task. Here, investigators will use&#xD;
      B-SNIP-based observations in already-characterized B-SNIP subjects, to predict in which&#xD;
      individuals CBD engages a theoretically-based brain target. In turn (in future planned&#xD;
      studies) such engagement may predict CBD treatment responders. At present, CBD is still an&#xD;
      experimental drug for psychosis treatment (although now FDA-approved for treatment of&#xD;
      specific types of childhood seizures), but one with a rather benign side-effect profile that&#xD;
      could easily be added to ongoing antipsychotic treatment. The purpose of the study is to&#xD;
      study response to a single, acute dose of CBD compared to placebo, under double-blind&#xD;
      conditions in a small-scale pilot study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects will receive both the study drug and placebo.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CBD dose-response for fMRI Hippocampal BOLD values</measure>
    <time_frame>Post drug administration at 3 hours</time_frame>
    <description>Primary outcome of fMRI-measured hippocampus BOLD values during memory recall task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CBD</condition>
  <arm_group>
    <arm_group_label>Patients with psychosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People who do not have a diagnosis of schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>Oral gel capsule CBD</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Patients with psychosis</arm_group_label>
    <other_name>CBD Oil</other_name>
    <other_name>Food grade CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral gel capsule placebo</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Patients with psychosis</arm_group_label>
    <other_name>Placebo CBD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50y/o&#xD;
&#xD;
          -  Males and females of all races and ethnicities&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Able to read, speak, and understand English&#xD;
&#xD;
          -  Meet DSM-IV (SCID-based) criteria for schizophrenia, schizoaffective disorder, bipolar&#xD;
             I disorder with psychotic features OR healthy controlled with no diagnosed severe&#xD;
             mental illness&#xD;
&#xD;
          -  No history of adverse normal baseline values for liver function tests (LFTs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Strongly left-handed individuals defined as a 60:40 or greater ratio of left to right&#xD;
             hand preference (assessed using the Edinburgh Handedness Inventory)&#xD;
&#xD;
          -  Premorbid intellectual ability estimate below 70 (WRAT-4, Word Reading subtest,&#xD;
             age-corrected standardized score)&#xD;
&#xD;
          -  Comorbid DSM-IV diagnosis of alcohol or substance abuse in prior 1 month or substance&#xD;
             dependence in prior 3 months&#xD;
&#xD;
          -  Neurological (e.g., seizure disorder, stroke, traumatic brain injury with a loss of&#xD;
             consciousness â‰¥ 30min) or severe medical condition (e.g., decompensated cardiovascular&#xD;
             disorder, AIDS) that may affect central nervous system function&#xD;
&#xD;
          -  Concomitant medications that may interact with study drug adversely such as platelet&#xD;
             inhibitors, benzodiazepines, or valproate&#xD;
&#xD;
          -  Initial detection of abnormal liver function tests or previous medical history of&#xD;
             abnormal liver function or liver disease&#xD;
&#xD;
          -  Vulnerable populations (e.g., pregnant, nursing, incarcerated); unwilling to use&#xD;
             reliable means of contraception&#xD;
&#xD;
          -  High risk for suicide defined as more than 1 attempt in past 12 months that required&#xD;
             medical attention, any attempt in the past 3 months or current suicidal ideation with&#xD;
             plan and intent such that outpatient care is precluded&#xD;
&#xD;
          -  Current homicidal ideation with plan and intent such that outpatient care is precluded&#xD;
&#xD;
          -  Positive result on breathalyzer or positive urine toxicology test for any substance,&#xD;
             including CBD&#xD;
&#xD;
          -  History of prior allergic reaction with CBD or CBD-containing products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Godfrey Pearlson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Founding Director Olin Research Center; Professor Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Boyle, BA</last_name>
    <phone>860-545-7548</phone>
    <email>catherine.boyle@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana King</last_name>
    <phone>860-545-7563</phone>
    <email>diana.king@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Diana King</last_name>
      <phone>860-545-7563</phone>
      <email>diana.king@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Godfrey Pearlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Godfrey Pearlson</investigator_full_name>
    <investigator_title>Founding Director Olin Neuropsychiatry Research Center; Professor Yale University</investigator_title>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>Memory</keyword>
  <keyword>MRI</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

